title: Synchronising oestrus with oestradiol benzoate after using a two-dose prostaglandin treatment to synchronise luteolysis in dairy heifers.
abstract: OBJECTIVE
  To compare the reproductive performance and pattern of onset of oestrus in dairy heifers in which oestrous cycles were synchronised with two doses of prostaglandin (PG) F2alpha and oestrus was synchronised with oestradiol benzoate (ODB).
  
  
  METHODS
  Dairy heifers in two herds (herd A, n = 192; herd B, n = 267) were treated with two doses of an analogue of PGF2alpha (cloprostenol, 375 microg, IM) 12 days apart. Heifers not detected in oestrus 48 h after the last dose of PGF2alpha were either left untreated (No ODB, n = 147) or treated with ODB (0.75 mg IM, n = 126). Onset of oestrus was monitored at 0, 24, 48, 80, 96 and 120 h after the last dose of PGF2alpha Heifers were inseminated on detection of oestrus.
  
  
  RESULTS
  After the last dose of PGF2alpha, oestrous detection rates at 80 h (43.5 vs 72.6%, P < 0.001), 96 h (74.1 vs 84.9%, P =0.025) and 120 h (78.2 vs 86.3%, P = 0.082) were less in the No ODB compared to the ODB heifers, respectively. Conception rates (percentage pregnant that were inseminated) were greater in the No ODB compared to the ODB heifers (64.3% vs 47.6%, respectively; P = 0.006), while pregnancy rates (percentage pregnant that were treated) were also greater in the No ODB compared to the ODB heifers, but differences were not significant (50.3% vs 41.1%, respectively; P = 0.068).
  
  
  CONCLUSIONS
  Administration of ODB to heifers not in oestrus 48 h after a two-dose PGF2alpha treatment increases the percentage of heifers detected in oestrus by 80 h, 96 h and 120 h after treatment, by an estimated 29%, 11% and 8%, respectively. However, administration of ODB decreases conception rates by an estimated 17%, and may decrease pregnancy rates (estimated 9% difference). Results are consistent with the hypothesis that ODB can increase submission rates but reduce conception rates following a two dose treatment with PGF2alpha.
authors.affiliation: Probreed RMS Pty Ltd, PO Box 241, Werribee, Victoria.
authors.forename: J
authors.initials: J
authors.lastname: Cavalieri
authors.forename: G
authors.initials: G
authors.lastname: Hepworth
authors.forename: L A
authors.initials: LA
authors.lastname: Fitzpatrick
mesh_terms: D000818:Animals; D002417:Cattle / Q000502:physiology*; D003008:Cloprostenol / Q000008:administration & dosage*; D003338:Corpus Luteum / Q000187:drug effects; D003612:Dairying; D004334:Drug Administration Schedule; D004958:Estradiol / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D004971:Estrus / Q000187:drug effects*; D004973:Estrus Synchronization; D005260:Female; D007273:Injections, Intramuscular / Q000662:veterinary; D007986:Luteinizing Hormone / Q000378:metabolism; D011247:Pregnancy; D018873:Pregnancy Rate
chemical_list: C074283:estradiol 3-benzoate; D003008:Cloprostenol; D004958:Estradiol; D007986:Luteinizing Hormone